ReviewCurrent drug targets2026
Proteasome Fine-Tunes the Generation of Antimicrobial Peptides.
Review in Current drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial peptides (AMPs), part of the body's innate immune response, are natural compounds that inhibit bacteria during bacterial infections. Despite their important role in counteracting cellular pathogens, the precise mechanism of generating AMPs in response to bacterial infection remains elusive. However, recent findings demonstrate that the proteasome, a cellular complex involved in the degradation of intracellular proteins, plays a key role in generating AMPs during bacterial infection. Intriguingly, bacterial infections have been shown to mediate the remodeling of the proteasome, resulting in altered cleavage activity that increases the generation of antimicrobial peptides and helps reduce intracellular bacterial load. Additionally, the 11S proteasome subunit PSME3 has been identified as the key regulatory particle responsible for triggering proteasome remodeling in response to bacterial stress. Remarkably, given the burgeoning research on antimicrobial agents, the recent findings uncover an important anti-bacterial functional role of the proteasome and open avenues for investigating strategies to modulate or enhance the cell's natural defense against pathogens to develop new antimicrobial therapeutics.
Indexed as
Identifiers
40999613What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.